تقرير
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
| العنوان: | Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. |
|---|---|
| المؤلفون: | Helgadottir H; Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital., Kis L; Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital., Ljungman P; Departments of Allogeneic Stem Cell Transplantation and Hematology, Karolinska University Hospital.; Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Larkin J; Melanoma Unit, Royal Marsden NHS Foundation Trust, London.; Royal Marsden Hospital, London, UK., Kefford R; Westmead Hospital, Melanoma Institute Australia and Macquarie University, Sydney, Australia., Ascierto PA; Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori di Napoli Fondazione 'G. Pascale', Naples, Italy., Hansson J; Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital., Masucci G; Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital. |
| المصدر: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2017 Jul 01; Vol. 28 (7), pp. 1672-1673. |
| نوع المنشور: | Case Reports; Letter; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : London : Elsevier Original Publication: Dordrecht ; Boston : Kluwer Academic Publishers, c1990- |
| مواضيع طبية MeSH: | Anemia, Aplastic/*chemically induced , Antineoplastic Combined Chemotherapy Protocols/*adverse effects , Melanoma/*drug therapy, Anemia, Aplastic/blood ; Anemia, Aplastic/immunology ; Antibodies, Monoclonal ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/immunology ; Female ; Humans ; Ipilimumab/administration & dosage ; Melanoma/blood ; Melanoma/immunology ; Melanoma/pathology ; Middle Aged ; Neoplasm Metastasis ; Nivolumab ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/immunology |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (CTLA-4 Antigen) 0 (CTLA4 protein, human) 0 (Ipilimumab) 0 (PDCD1 protein, human) 0 (Programmed Cell Death 1 Receptor) 31YO63LBSN (Nivolumab) |
| تواريخ الأحداث: | Date Created: 20170414 Date Completed: 20180523 Latest Revision: 20220331 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1093/annonc/mdx177 |
| PMID: | 28407116 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1569-8041 |
|---|---|
| DOI: | 10.1093/annonc/mdx177 |